Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin, Relapsed Refractory Multiple Myeloma
Conditions
Keywords
CAR-T, IL-15, malignant hematological tumors
Brief summary
The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.
Detailed description
The main objective is to evaluate the safety and efficacy of a novel CAR-T therapy that co expresses IL-15 in malignant hematological tumors. The secondary objective is to investigate the in vivo survival time of the novel CAR-T co expressing IL-15 and the activation and proliferation of a novel CAR-T co expressing IL-15 in vivo.
Interventions
The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\ 30 mL normal saline.
Sponsors
Shanxi Bethune Hospital
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* I (or the authorized representative/legal guardian) agree and have signed an informed consent form, and am willing and capable of following the planned visits, research treatments, laboratory tests, and other research procedures; * Histopathological or flow cytometric diagnosis of CD19 and/or CD22, BCMA-positive hematological malignancies; -≥15 years old, ≤80 years old; * If you meet one of the following three conditions, you can be included in the group:-Patients with recurrent or refractory hematologic malignancies treated with one standard chemotherapy regimen and one salvage regimen;-Minimal residual lesions persist after treatment with one standard chemotherapy regimen and one salvage regimen;-Patients with recurrence after hematopoietic stem cell transplantation; * Estimated survival ≥12 weeks; * Good heart, liver and kidney function: * Serum creatinine ≤ 1.5 mg/dL (1mg/dl=88.4umol/L); Serum ALT/AST ≤ 2.5 ULN; Total bilirubin ≤ 1.5 mg/dl (1mg/dl=17.1umol/L): * Cardiac ejection fraction ≥50%, cardiac ultrasound showed centropericardial effusion: * Eastern Oncology Collaborative Group Activity Status Score (ECOG)0-3; * Able to understand and voluntarily sign informed consent; If the subject is a child, the guardian will sign the informed consent. If the answer to any of the above is "no", the subject will not be allowed to participate in this study.
Exclusion criteria
* Have a New York Heart Association (NYHA) classification > Class III heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically prominent heart disease within one year prior to signing the consent form, or have a QTC interval >480ms at the time of screening (QTC interval is calculated using the Fridericia formula); * Have active GVHD, or need immunosuppressants; * Other malignancies were present within 5 years prior to screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and breast ductal carcinoma in situ after radical resection of local prostate cancer; * The presence of an active or uncontrolled infection requiring systemic treatment (except for mild genitourinary and upper respiratory tract infections) in the 7 days prior to screening; * If HBSAg or HbCAb positive peripheral blood hepatitis B virus (HBV)DNA is higher than the lower limit of detection, it should be excluded. If hepatitis C virus (HCV) antibody positive, peripheral blood HCVRNA positive should be excluded; (HIV) antibody-positive; -Cytomegalovirus (CMV)DNA test positive for human immunodeficiency virus; Those who test positive for Treponema pallidum specific antibody (TPPA) should be excluded; * Participating in another clinical trial within 4 weeks prior to the signing of the informed consent, or the signing date of the informed consent is still within 5 half-lives of the drug (whichever is longer) since the last drug used in the last clinical trial; * A history of severe allergy to biological products; * Systemic diseases that are considered unstable by the investigator: including but not -limited to severe liver, kidney, or metabolic diseases requiring medical treatment; * Pregnant or lactating women, and female subjects who plan pregnancy within 2 years after cell transfusion or male subjects whose partner plans pregnancy within 2 years after cell transfusion; * Conditions that the investigator believes may increase the risk to the subject or interfere with the test results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| monitor the survival time of CAR-T in vivo | 6 months | The survival of CAR-T in vivo will be monitored periodically by flow cytometry after CAR T reinfusion. |
| Record antitumor effects after reinfusion of CAR-T | 28 days | Determine partial response (PR) or complete response (CR) for subjects with active disease. In view of the small number of subjects, remission should be recorded in detail; For subjects treated with minimal residual lesion (MRD), MRD clearance results were recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | 3 years | DFS was calculated from the first CAR-T cell infusion to death, progression of the disease, relapse or gene recurrence, whichever came first, or last visit. |
| Overall Survival | 3 years | OS was calculated from the first CAR-T cell infusion to death or last follow-up |
Other
| Measure | Time frame | Description |
|---|---|---|
| The copy number of CAR-T cells | 12 months | The copy number of CAR-T cells amplified in peripheral blood after administration |
Countries
China
Contacts
Primary ContactJIA WEI
Outcome results
None listed